Midatech Pharma PLC (MTP)

[BioSpecialist]

5 Marketed Products + Oral thin-film Insulin with P2 Results in April which has Multiple Blockbuster Potential and many other drugs in clinical Trials . this undiscovered low float stock is brutally undervalued alone the marketed drugs will drive this Company into profitability within 2 years . If the Phase 2 results of the Oral Insulin in April is positive then this low float stock could explode like Oramed (ORMP) did in end 2013 to early 2014 which send the stock from $10 to almost $30 within days .

This Undiscovered Stock with a Market Cap of less than $60 Million and over $30 Million in Cash is heavily underpriced but this will Change very soon especially when the Outcome of the Oral Insulin is positive .GL



Midatech Pharma (MTP)

Market Cap: $59.5 Million
Cash: $35 Million
Price: $3.58

Shares Out: 16.6 Million


MidatechPharma US: Focus On Oncology and Supportive Care:

Zuplenz: Oral film for Chemo/Radio Rx Induced Nausea & Vomiting Highly effective 5HT3 antagonist Launch H1 2016

Gelclair: Hyaluronic Acid Oral Gel For Oral Mucositis 85-100% of H&N cancer patients on chemo/radiotherapy develop OM Leads market in US strong growth expected 2016

Aquoral:Oral Spray Treatment For Dry Mouth Xerostomia

Oravig:Buccal Tablet For Oral Candidiasis In Adults Serious complication for patients undergoing radio/chemotherapy Launched H2 2015 –first full year of sales 2016

Ferralet90: Dual Iron Delivery Anaemia treatment


Oral thin-film Insulin:

From positive Phase I clinical trial results it has been demonstrated that the transbuccal insulin formulation is safe and well tolerated in healthy human volunteers and that it is absorbed faster and utilised more quickly than subcutaneous insulin.

•Phase I (2012) -No safety concerns
-Suggests insulin enters blood, faster to max effect

•Phase IIa-Completed in life phase January 2016
-Clinical Study Report is expected in April 2016

•Phase II data will inform strategic opportunities (license or exit)

“Diabetes incidence is forecast to hit 500m people, globally, by 2025; with our partnered transbuccal insulin strip, MSL-001 is targeting a $20 billion market, adding significant revenue potential to our growing portfolio of products.”



Jim Phillips Presents on behalf of Midatech Pharma at the Biotech Capital Conference

March Presentation
http://www.midatechpharma.com/uploads/Midatech%20Deck%202016%20march%2003%20Com.pdf


Major shareholders
http://www.midatechpharma.com/investors/share-information.html


Edison Research
http://www.edisoninvestmentresearch.com/research/report/midatech4/preview/

Valuation: Increased to $221.0m from $200.7m

Our valuation for Midatech increases to $221.0m from $200.7m previously (or $13.29/ADR from $14.45/ADR, as we now incorporate the acquisitions of DARA and Zuplenz. Our valuation for DARA is based on forecast future operating cash flows (excluding potential payments on contingent value rights that are dependent on sales milestones, which exceed our relatively conservative projections). Additionally, we adjust our valuation for Midatech upward as our model has been rolled forward by six months and rebased to 2016.